Bit Bio secures $41.5 million of funding from top life sciences investors
Bit Bio’s aim is to decode “cellular identity” in order to generate every cell type of the human body
25-Jun-2020 -
Bit Bio, a Cambridge-based synthetic biology company combining data science and biology to code cells for the wellbeing of humanity, announced the close of a $41.5 million Series A investment, bringing the company’s total funding to $50 million. In a strong statement of support for the company’s ...
Series A financing
stem cell reprogramming
stem cells